

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 August 2024 (08.08.2024)



(10) International Publication Number
WO 2024/163905 A1

(51) International Patent Classification:

A61K 47/54 (2017.01) C07C 233/36 (2006.01)
A61K 47/68 (2017.01) C07C 217/08 (2006.01)
A61K 47/69 (2017.01) C07C 237/12 (2006.01)
A61K 48/00 (2006.01) C07C 323/52 (2006.01)
C12N 15/88 (2006.01) C07C 327/28 (2006.01)

(21) International Application Number:

PCT/US2024/014265

(22) International Filing Date:

02 February 2024 (02.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/443,223	03 February 2023 (03.02.2023)	US
63/463,252	01 May 2023 (01.05.2023)	US
63/467,282	17 May 2023 (17.05.2023)	US

(71) Applicants: **GENZYME CORPORATION** [US/US];
450 Water Street, Cambridge, Massachusetts 02141 (US).
TIDAL THERAPEUTICS, INC. [US/US]; 700 Main
Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **BORGES, Christopher**; c/o Sanofi U.S.,
Patent Department, 450 Water Street, Cambridge, Massa-
chusetts 02141 (US). **BOESCH, Austin Wayne**; c/o Sanofi
U.S., Patent Department, 450 Water Street, Cambridge,

Massachusetts 02141 (US). **DRUMMOND, Daryl Clark**;
c/o Sanofi U.S., Patent Department, 450 Water Street,
Cambridge, Massachusetts 02141 (US). **HOPE, Jacob**; c/
o Sanofi U.S., Patent Department, 450 Water Street, Cam-
bridge, Massachusetts 02141 (US).

(74) Agent: **BLOCH, Sarah E.** et al.; Morrison & Foerster LLP,
425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOF




FIG. 1

(57) Abstract: Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., HSC), and methods of making and using such lipids and targeted lipid nanoparticles.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*